TITLE

High Expression of Dihydropyrimidine Dehydrogenase in Lung Adenocarcinoma is Associated With Mutations in Epidermal Growth Factor Receptor: Implications for the Treatment of Non--Small-Cell Lung Cancer Using 5-Fluorouracil

AUTHOR(S)
Koji Mochinaga; Tomoshi Tsuchiya; Toshiya Nagasaki; Junichi Arai; Tetsuro Tominaga; Naoya Yamasaki; Keitaro Matsumoto; Takuro Miyazaki; Atsushi Nanashima; Tomayoshi Hayashi; Kazuhiro Tsukamoto; Takeshi Nagayasu
PUB. DATE
March 2014
SOURCE
Clinical Lung Cancer;Mar2014, Vol. 15 Issue 2, p136
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
94754948

 

Related Articles

  • Cancer: A Ras and NF-kappaB pas de deux. Chenette, Emily J. // Nature Reviews Drug Discovery;Dec2009, Vol. 8 Issue 12, p932 

    The article offers information on report published in the journal "Nature," that demonstrates the importance of nuclear factor-KB (NF-KB) signalling in the survival of cancer cells with mutations in KRAS, detected in non-small-cell lung cancer (NSCLC). The study investigates the tumour cell in...

  • Biomarker Testing in Non-Small Cell Lung Cancer. Bernicker@HoustonMethodist.org, Eric Bernicker // Archives of Pathology & Laboratory Medicine;Apr2015, Vol. 139 Issue 4, p448 

    The article discusses the use of biomarker testing in non-small cell lung cancer patients. Also tackled are clinical trials conducted for the activation of epidermal growth factor receptor (EGFR) mutation. Mentioned is the approval of the U.S. Food and Drug Administration for the Crizotinib drug...

  • Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Pühringer-Oppermann, F. A.; Stein, H. J.; Sarbia, M. // Diseases of the Esophagus;Feb2007, Vol. 20 Issue 1, p9 

    Epidermal growth factor receptor is over-expressed in several tumors and is the target for the tyrosine kinase inhibitor gefitinib. This receptor is also over-expressed in esophageal adenocarcinomas. In non-small cell lung cancer, specific somatic mutations residing in the epidermal growth...

  • ORAL PILL MATCHES CHEMO FOR LUNG CANCER.  // RN;Jan2009, Vol. 72 Issue 1, p21 

    The article reports that researchers have found that gefitinib (Iressa) is a second-line treatment that is as effective as chemotherapy for treating non-small-cell lung cancer. It reports that patients who expressed an elevated level of the epidermal growth factor receptor mutation had no...

  • Gene Mutations in Lung Cancer: Promising Predictive Factors for the Success of Molecular Therapy. Inoue, Akira; Nukiwa, Toshihiro // PLoS Medicine;Jan2005, Vol. 2 Issue 1, p20 

    Discusses gene mutations in lung cancer and the success of molecular therapy. Information on the process of molecular therapy for non-small-cell lung cancer (NSCLC); Description of the epidermal growth factor receptor gene mutations in NSCLC; Information on the therapeutic implications of...

  • Lung Carcinoma Morphology or Mutational Profile: That Is the Question. Dacic, Sanja // Archives of Pathology & Laboratory Medicine;Oct2011, Vol. 135 Issue 10, p1242 

    The article discusses non-small cell lung carcinoma (NSCLC) testing, and the correlation between epidermal growth factor receptor (EGFR) mutations and morphologic types of adenocarcinoma. It mentions that a proposal for multidisciplinary classification of lung adenocarcinoma was published...

  • Diagnosis and Prognosis. Gandhi, Leena; Linden, Philip; Plant, Paul // Current Medical Literature: Lung Cancer;2012, Vol. 5 Issue 4, p119 

    The article presents several studies about lung cancer. A Sequential Tarceva in Unresectable Non-Small-Cell Lung Carcinoma (NSCLC) study on the drug erlotinib showed a prolonged progression-free survival (PFS) rate in NSCLC patients. Another study determined the benefits of epidermal growth...

  • Oncology.  // CenterWatch Weekly;6/2/2014, Vol. 18 Issue 22, p9 

    The article focuses on the report provided by the pharmaceutical company Boehringer Ingelheim concerning the result of the two phase III trials for the treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation using of afatinib drug.

  • New Molecular Targets in Lung Adenocarcinoma. Kelleher, Fergal C.; Colebatch, Andrew J.; Rao, Aparna // Oncology & Hematology Review;Winter2013, Vol. 9 Issue 2, p122 

    Lung cancer is designated as either non-small-cell lung cancer (NSCLC) or small-cell lung cancer. There are three subtypes of NSCLC: adenocarcinoma (48 %), squamous cell carcinoma (28 %), and large-cell carcinoma (24 %). Epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma...

  • Predicting Sensitivity of Non—Small-Cell Lung Cancer to Gefitinib: Is There a Role for P-Akt? Pao, William; Miller, Vincent A.; Venkatraman, Ennapadam; Kris, Mark G. // JNCI: Journal of the National Cancer Institute;8/4/2004, Vol. 96 Issue 15, p1117 

    Explores the role of phosphatidylinositol 3-kinase/Akt in predicting sensitivity of non-small-cell lung cancer (NSCLC) to gefitinib. Inhibition of epidermal growth factor receptor (EGFR) by gefitinib; Association of mutations in the tyrosine kinase domain of EGFR with gefitinib sensitivity in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics